Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 randomized placebo-controlled dose-escalation study of subcutaneous glutazumab in adults with type 2 diabetes mellitus
ChiCTR1900024897Phase 2Completed
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glutazumab in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Blood concentration of study drug, Immunogenicity of anti-drug antibodies and 2 more. Started Jan 2019; status: completed.
02
Drugs
glutazumab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900024897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024897.